FDA Approves IV Maintenance Dosing Of Leqembi® (Lecanemab-Irmb) For The Treatment Of Early Alzheimer's Disease In The US
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
Medindia6m
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment   TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...
Hosted on MSN17m
Why Can’t Older Phones Work With 5G?
It's an extreme example for sure, but it really all comes down to older phones not having the right antennas, radio hardware, ...
Hosted on MSN1h
HONOR X9c 5G is now available nationwide
The HONOR X9c 5G is now officially available nationwide. For those of you who have pre-ordered — Congratulations! Because you ...